GlassScriptPhysician profile
Rose Knight
NPI 1699364307
$10,811.90
in general payments reported to CMS, 2019-2025
35 companies · $3,614 in 2025
The $3,614 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $968 · 2023: $2,715 · 2024: $3,311 · 2025: $3,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,129 · Education: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,128.79 |
| Education | $510.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,680.17 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,102.62 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $934.18 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
| Lilly USA, LLC | $900.94 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $898.07 | 2023-2025 | Zoryve |
| Genzyme Corporation | $774.52 | 2022-2025 | |
| Incyte Corporation | $554.63 | 2021-2025 | Opzelura |
| Pfizer INC. | $441.67 | 2022-2025 | |
| Ucb, INC. | $392.43 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $385.80 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $353.73 | 2022-2025 | |
| Leo Pharma INC. | $274.31 | 2022-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $256.89 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $216.39 | 2024 | Tremfya |
| Galderma Laboratories, L.P. | $199.57 | 2023-2025 | Nemluvio, Aklief, Epsolay |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $192.04 | 2022-2025 | Seysara, Klisyri |
| Medimetriks Pharmaceuticals, INC. | $164.54 | 2023-2025 | Neo-Synalar, Clindacin Etz |
| Botanix Sb INC | $155.52 | 2025 | Sofdra |
| Amgen INC. | $133.23 | 2022-2024 | Otezla |
| Journey Medical Corporation | $124.33 | 2022-2025 | |
| Kyowa Kirin, INC. | $120.83 | 2024 | Poteligeo |
| Organon LLC | $111.43 | 2025 | Vtama |
| Revance Therapeutics, INC. | $76.32 | 2024 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.88 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.27 | 2022-2024 | |
| Fidia Pharma USA INC. | $43.02 | 2024 | |
| Biofrontera INC. | $41.89 | 2025 | Ameluz |
| Cipher Pharmaceuticals US LLC | $28.73 | 2025 | Spinosad, Natroba |
| Sebela Pharmaceuticals INC. | $28.53 | 2022-2023 | Pramosone, Naftin |
| Nabriva Therapeutics, Plc | $21.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.10 | 2022 | |
| Blueprint Medicines Corporation | $17.64 | 2023 | |
| Paratek Pharmaceuticals, INC. | $15.47 | 2024 | Nuzyra |
| Optinose US, INC. | $14.46 | 2021 | |
| Verrica Pharmaceuticals INC. | $13.20 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.